Cover
| Cover | Jun. 14, 2024 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | Add'l Exhibit |
| Document Period End Date | Jun. 14, 2024 |
| Entity File Number | 001-39126 |
| Entity Registrant Name | CNS Pharmaceuticals, Inc. |
| Entity Central Index Key | 0001729427 |
| Entity Tax Identification Number | 82-2318545 |
| Entity Incorporation, State or Country Code | NV |
| Entity Address, Address Line One | 2100 West Loop South |
| Entity Address, Address Line Two | Suite 900 |
| Entity Address, City or Town | Houston |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 77027 |
| City Area Code | (800) |
| Local Phone Number | 946-9185 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, par value $0.001 per share |
| Trading Symbol | CNSP |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |